Related Experiment Videos

[Acquired cytomegalovirus infection in infants. A case successfully treated with ganciclovir]

R Dündaröz1, R Akin, V Okutan

  • 1Service de Pédiatrie, Hôpital de Mevki Asker Hastanesi, Diskapi, Ankara, Turquie.

Presse Medicale (Paris, France : 1983)
|June 21, 1997
PubMed

Insights

Ganciclovir effectively treated cytomegalovirus (CMV) hepatitis in an infant acquired postnatally. This antiviral medication offers a safe and successful treatment option for infants with symptomatic acquired CMV infections.

Area of Science:

  • Virology
  • Pediatric Infectious Diseases
  • Pharmacology

Background:

  • Cytomegalovirus (CMV) infection can be severe, especially congenital cases.
  • Postnatally acquired CMV infections, while less severe, can still lead to complications and warrant treatment.
  • Hepatitis is a potential manifestation of CMV infection in infants.

Observation:

  • A 2.5-year-old infant presented with hepatitis attributed to a postnatally acquired CMV infection.
  • The infant received a course of intravenous ganciclovir, with dosage adjustments over two months.
  • No adverse effects or toxicity were noted during the treatment period.

Findings:

  • The infant recovered completely from CMV hepatitis without any sequelae.
  • Intravenous ganciclovir demonstrated efficacy in treating symptomatic acquired CMV infection in this pediatric case.
  • The treatment regimen was well-tolerated by the infant.

Implications:

  • Ganciclovir is a viable therapeutic option for symptomatic, postnatally acquired CMV infections in infants.
  • This case supports the use of ganciclovir beyond severe congenital CMV infections.
  • Further research into ganciclovir's role in managing various presentations of acquired CMV in neonates and infants is warranted.
Abstract

Related Concept Videos